渥太华医院打疫苗

  • 主题发起人 主题发起人 SFU
  • 开始时间 开始时间

SFU

资深人士
注册
2007-07-26
消息
2,590
荣誉分数
611
声望点数
223
今天突然收到渥太华医院Email, 邀我注册打疫苗。有没有人也收到过啊,我年龄没到,也不是医护人员,感觉是插队了,是不是因为以前住院过啊?
 
不用考虑太多,马上注册去打。这个应该是pfizer.
 
好像去了要看proof of employment。
 
应该是给医护的,需要带证明工作牌
 
好像去了要看proof of employment。
E-mail 上要你带什么?一般就是健康卡,还有填那张Vaccine Consent Form. 你可以事先下载填好以节省时间。
 
如果有基础疾病的是不是也提前打?
 
楼主应该是通过省卫生网注册的,只有符合条件的才能注册成功,所以应该是符合要求?一般这上面注册的会分到Queensway 和渥太华医院。
 
如果有基础疾病的是不是也提前打?
我就担心是这个原因,错过了就可惜了。但也不想插队占便宜,再等个把月也无所谓
 
你还是配合他们吧。不是插队。
 
楼主应该是通过省卫生网注册的,只有符合条件的才能注册成功,所以应该是符合要求?一般这上面注册的会分到Queensway 和渥太华医院。
疫苗约在星期五打,倒是挺快的。email给他们在确认一下吧,也没有电话什么的
 
我就担心是这个原因,错过了就可惜了。但也不想插队占便宜,再等个把月也无所谓
现在的不是主要针对医务的,主要医务都打完两针了。现在范围大很多,你提到雇佣证明,说明你可能是在服务社区类工作,把最近的工资单之类带上就可以。
 
我就担心是这个原因,错过了就可惜了。但也不想插队占便宜,再等个把月也无所谓

那里可是紧俏的辉瑞疫苗啊,让你打就赶快打,别磨叽了。

好多人做梦都想打辉瑞呢……
 
今天去打疫苗,只有辉瑞,没有灭活的。气死我了。
 
今天突然收到渥太华医院Email, 邀我注册打疫苗。有没有人也收到过啊,我年龄没到,也不是医护人员,感觉是插队了,是不是因为以前住院过啊?
我好像见过渥太华医院研发疫苗,征集志愿者,别是这个吧!

Ottawa-area residents invited to participate in COVID-19 vaccine trial​

Study at The Ottawa Hospital testing vaccine candidate developed by Ottawa-based company VBI

March 9, 2021
MichaelineMcGuinty.jpg
"By participating in this trial, volunteers will be advancing research that will help in the fight against COVID-19 and other infectious diseases as well,” said Dr. Michaeline McGuinty.Healthy adults are invited to participate in a clinical trial at The Ottawa Hospital to test a COVID-19 vaccine candidate developed by VBI Vaccines Inc., a biotechnology company with Ottawa-based research and development facilities. The first phase of the trial is expected to include 60 healthy adults age 18-54, while the second phase could expand participants to all ages 18 and over. The Ottawa Hospital site, led by Dr. Bill Cameron and Dr. Michaeline McGuinty, is one of nine sites in Canada enrolling participants.
“It is essential that we continue to develop and test COVID-19 vaccines because this virus will be with us for some time, and many vaccines will be needed to reach everyone,” said Dr. Bill Cameron, Medical Director of Clinical Research and infectious disease specialist at The Ottawa Hospital and professor at the University of Ottawa.
“By participating in this trial, volunteers will be advancing research that will help in the fight against COVID-19 and other infectious diseases as well,” said Dr. Michaeline McGuinty, infectious disease specialist and clinician investigator at The Ottawa Hospital and lecturer at the University of Ottawa.
The vaccine candidate, called VBI-2902, contains the spike protein from SARS-CoV-2 (the virus that causes COVID-19) embedded in a synthetic lipid envelope. It is referred to as an enveloped virus-like particle (eVLP) because, to the immune system, the vaccine particles mimic the natural presentation of viruses, but have no infectious genetic material and cannot replicate.
“We are excited to begin the clinical assessment of our eVLP approach to vaccination against coronaviruses with this first clinical study of VBI-2902,” said Jeff Baxter, President and CEO of VBI in a media release from VBI. “We are committed to bringing forward candidates that add meaningful clinical and medical benefit to those already approved – be it as a one-dose administration, more durable immune responses, and/or providing broader protection against known and emerging variants of COVID-19. We are grateful for the support of our Canadian partners at the Department of Innovation, Science and Economic Development, the National Research Council, and Resilience Biotechnologies. We look forward to sharing initial data from this study in
BillCameron400SQ.jpg
"It is essential that we continue to develop and test COVID-19 vaccines because this virus will be with us for some time, and many vaccines will be needed to reach everyone,” said Dr. Bill Cameron.the coming months as well as initiating clinical studies of our pan-coronavirus vaccine candidate, expected later in 2021.”
VBI was founded in Ottawa by Dr. Francisco Diaz-Mitoma, formerly a scientist at CHEO and professor at the University of Ottawa, and currently Chief Medical Officer of VBI. The company maintains research and development facilities in Ottawa, with corporate headquarters in the United States and a research and manufacturing facility in Israel. VBI is also working with The Ottawa Hospital’s Biotherapeutics Manufacturing Centre to support manufacturing of its vaccine cell line.
Individuals who participate in the VBI-2902 trial will be randomized to receive different doses of the experimental vaccine or a placebo. Neither the participants nor the study team will know which group a participant is in until the study ends. Safety, tolerability and immune responses will be evaluated. Further trial details are available at clinicaltrials.gov. Ottawa residents who are interested in participating can call The Ottawa Hospital’s Clinical Investigation Unit at 613-737-8811 or email ciu@toh.ca to learn more.
About The Ottawa Hospital
The Ottawa Hospital is one of Canada’s top learning and research hospitals, where excellent care is inspired by research and driven by compassion. As the third-largest employer in Ottawa, our support staff, researchers, nurses, physicians, and volunteers never stop seeking solutions to the most complex health-care challenges. Our multi-campus hospital, affiliated with the University of Ottawa, attracts some of the most influential scientific minds from around the world. Backed by generous support from the community, we are committed to providing the world-class, compassionate care we would want for our loved ones. www.ohri.ca
About the University of Ottawa
The University of Ottawa is home to over 50,000 students, faculty and staff, who live, work and study in both French and English. Our campus is a crossroads of cultures and ideas, where bold minds come together to inspire game-changing ideas. We are one of Canada’s top 10 research universities—our professors and researchers explore new approaches to today’s challenges. One of a handful of Canadian universities ranked among the top 200 in the world, we attract exceptional thinkers and welcome diverse perspectives from across the globe. www.uottawa.ca
Media contact
Jenn Ganton
jganton@ohri.ca
613-614-5253
 
最后编辑:
后退
顶部